Metadon Nordic Drugs

Methadone Hydrochloride, the active ingredient in Metadon, is an opioid agonist presented as an oral formulation for oral use. It is employed in the management of opioid dependence and chronic pain, providing analgesia and reducing withdrawal symptoms in patients requiring long‑term opioid therapy.

GNH USA supplies Metadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metadon is an opioid agonist used in the treatment of conditions related to opioid pathways and chronic pain management. - Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Opioid substitution therapy: stabilizes opioid levels to reduce illicit opioid use.

Methadone may cause a range of adverse reactions, from mild to severe, which should be monitored during therapy.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea or vomiting: gastrointestinal upset. - Drowsiness or sedation: central nervous system depression. - Sweating: increased perspiration. - Dry mouth: reduced salivary flow. - Weight gain: increased appetite.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Cardiac arrhythmias: QT interval prolongation leading to torsades de pointes. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating Metadon therapy, several safety considerations are essential. - Assess cardiac history: evaluate risk of QT prolongation. - Review liver function: adjust use in hepatic impairment. - Monitor for respiratory depression: especially in opioid‑naïve patients. - Avoid abrupt discontinuation: taper dose to prevent withdrawal. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Methadone interacts with several drug classes that can alter its safety or effectiveness.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - CNS depressants (e.g., benzodiazepines, barbiturates): heightened respiratory depression. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise methadone levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antidepressants (e.g., SSRIs, SNRIs): monitor for additive serotonergic effects.